During her tenure at UBC, Zoubeidi and her research team developed the first drug that targets and blocks BRN2, thus stopping Neuroendocrine prostate cancer (NEPC) tumours and creating a possible treatment for the previously thought incurable disease.
[5] She continued her research into Hsp27 and received funding from the Michael Smith Career Investigator Award for her project Adaptive Stress Response Signaling Driving Treatment Resistance and Metastasis in Cancer.
[6] While serving in her role as an assistant professor, in collaboration with Vancouver Coastal Health, Zoubeidi continued to search for a cure for prostate cancer and led her research team to numerous discoveries.
[8] Following this discovery, she earned a three-year Translation Acceleration Grant from Prostate Cancer Canada and Movember to fund a project to develop blockers of BRN2, a gene linked to the growth of aggressive NPEC.
[12] By 2019, Zoubeidi and her research team developed the first drug that targets and blocks BRN2, thus stopping NEPC tumours and creating a possible treatment for the previously thought incurable disease.